Cornerstone Therapeutics brings advanced, professionally-scaled, organic horticultural practices and patient centered services to the new, highly regulated Massachusetts medical marijuana market.
Combining the expertise of Denver-based RiverRock Wellness, with experienced Boston area pharmaceutical and nonprofit executives, will allow access to pharmaceutical grade flower and Cannabinoid (CBD) products for certified patients within the Commonwealth.
A comprehensive understanding of the rules and regulations adopted by the Department of Public Health, and working relationships with officials in key municipalities, gives us an increased advantage in the competitive final application process.
Upon receipt of one or more licenses, our best-in-class operations should help us immediately realize significant market share. Combined with the ability to target patient needs through condition specific products, allows scalability to meet the Commonwealth’s projected sharp growth in demand.
Cornerstone Therapeutics will utilize the proprietary Blackmon Cultivation System which allows for cannabis products of exceptional yield and quality. While industry standard for yield, typically in a hydro, aero, or coco blend medium produces 1.25 lbs per 1000 watt light; the Blackmon Cultivation System increases yields by 60% (2 plus lbs per 1000 watt light), boosts cannabinoid profiles over 20%, and multiplies by-product extract (i.e. hashish) yields by 30%.
Cornerstone Therapeutics will offer one of the most effective and highest quality suite of products in the cannabis industry. Planned products will include: Over 60 cannabis strains (with potential to add additional strains based on consumer demand); A full line of edible products; Solvent and solvent less cannabis extracts; Priva line of cannabinoid capsule formulations and transdermal CBD patches.
With high yield cannabinoid strains and alternative CBD products, Cornerstone Therapeutics aligns its product lines with current medical literature and suggested treatment modalities using medicinal marijuana. This approach should prove favorable with regulators and we believe will positively position the company for potential suitors from mainstream industries once conditions are favorable.